Addison Capital CO Incyte Corp Transaction History

Addison Capital CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 12, 2021	SELL	$80.74 - $97.7 $200,073 - $242,100	-2,478 Closed	0 $0
Q2 2020 Jul 16, 2020	BUY	$74.18 - $108.93 $183,818 - $269,928	2,478 New	2,478 $258,000
Q1 2020 Apr 13, 2020	SELL	$63.18 - $85.97 $163,257 - $222,146	-2,584 Closed	0 $0
Q4 2019 Jan 10, 2020	SELL	$73.04 - $95.72 $32,868 - $43,074	-450 Reduced 14.83%	2,584 $226,000
Q2 2019 Jul 11, 2019	SELL	$73.52 - $88.7 $735 - $887	-10 Reduced 0.33%	3,034 $258,000
Q1 2019 Apr 10, 2019	SELL	$63.56 - $88.17 $15,572 - $21,601	-245 Reduced 7.45%	3,044 $262,000
Q4 2018 Jan 16, 2019	SELL	$58.5 - $69.94 $14,157 - $16,925	-242 Reduced 6.85%	3,289 $209,000
Q3 2018 Oct 09, 2018	BUY	$61.75 - $74.23 $218,039 - $262,106	3,531 New	3,531 $244,000
Q2 2018 Jul 11, 2018	SELL	$60.85 - $83.98 $465,502 - $642,447	-7,650 Closed	0 $0
Q1 2018 Apr 10, 2018	BUY	$83.06 - $100.98 $84,555 - $102,797	1,018 Added 15.35%	7,650 $637,000
Q4 2017 Jan 19, 2018	BUY	$93.56 - $116.6 $53,703 - $66,928	574 Added 9.48%	6,632 $628,000
Q3 2017 Oct 17, 2017	BUY	$109.15 - $138.27 $661,230 - $837,639	6,058	6,058 $707,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Addison Capital CO, based on Form 13F filings with the SEC.

Stay updated on Addison Capital CO with notifications on news.